| 产品编号 | bs-1485R |
| 英文名称 | BIN1 Rabbit pAb |
| 中文名称 | 桥连整合因子蛋白抗体 |
| 别 名 | BIN1_HUMAN; BIN1; Amphiphysin II; Amphiphysin-like protein; Box-dependent myc-interacting protein 1; Bridging integrator 1; AMPHL; BIN1_MOUSE; SH3 domain-containing protein 9; Sh3p9; BIN1_RAT; Amph2; |
| 研究领域 | 肿瘤 免疫学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 克 隆 号 | |
| 交叉反应 | (predicted: Human, Mouse, Rat, Dog, Cow, Horse, ) |
| 产品应用 | ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理论分子量 | 65 kDa |
| 细胞定位 | 细胞核 |
| 性 状 | Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BIN1: 101-200/593 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 缓 冲 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存条件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事项 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 产品介绍 |
The identification and analysis of tumor suppressors is of major importance for improved diagnosis and treatment of tumors. Bin1 (Box-dependent myc interacting protein 1, also known as SH3P9, amphiphysin II and amphl/amphiphysin-like) is a novel protein that has features of a tumor suppressor. Bin1 interacts with and inhibits the oncogenic activity of the myc oncoprotein that has a major role in many human cancers. The loss of Bin1 may contribute to growth deregulation in cancer cells in carcinoma of the breast, colon, lung, cervix, prostate and liver. Bin1 also interacts with HCV NS5A through its SH3 domain. Function: May be involved in regulation of synaptic vesicle endocytosis. May act as a tumor suppressor and inhibits malignant cell transformation. Subunit: Heterodimer with AMPH. Binds SH3GLB1 (By similarity). Interacts (via SH3 domain) with SYNJ1. Interacts (via SH3 domain) with DNM1. Isoform IIA interacts with CLTC. Isoform IIB does not interact with CLTC. Isoform IIC1 does not interact with CLTC. Isoform IIC2 does not interact with CLTC. Interacts with AP2A2. Interacts with AP2B1. Interacts with MYC (via N-terminal transactivation domain); the interaction requires the integrity of the conserved MYC box regions 1 and 2. Interacts with BIN2. Interacts (SH3 domain) with HCV NS5A. Subcellular Location: Isoform BIN1: Nucleus. Isoform IIA: Cytoplasm. Tissue Specificity: Ubiquitous. Highest expression in the brain and muscle. Isoform IIA is expressed only in the brain where it is concentrated in axon initial segments and nodes of Ranvier. Isoform BIN1 is widely expressed with highest expression in skeletal muscle. Post-translational modifications: Phosphorylated by protein kinase C. DISEASE: Myopathy, centronuclear, 2 (CNM2) [MIM:255200]: A congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Contains 1 BAR domain. Contains 1 SH3 domain. SWISS: O00499 Gene ID: 274 Database links: Entrez Gene: 274 Human Entrez Gene: 30948 Mouse Omim: 601248 Human SwissProt: O00499 Human SwissProt: O08539 Mouse Unigene: 193163 Human Unigene: 4383 Mouse Unigene: 17098 Rat 交换和转运（Trafficking and Transport） BIN1蛋白(bridging integrator protein 1)是一种新发现的具有抑癌特性的c-myc连接蛋白. |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
